LivaNova ($LIVN) now boasts both artificial heart valves to earn FDA approval in 2016. The company expects to launch the Crown PRT for the treatment of aortic valve disease in the coming months. "Crown PRT is a modern bioprosthesis enabling a simple, safe, reliable and reproducible cardiac surgery procedure for patients in need of an aortic valve replacement," said Dr. Rainald Seitelberger of Salzburg University Clinic in Austria, "Data have shown that phospholipids play an important role in the calcification process of bioprosthesis, and LivaNova's Crown PRT has proven to decrease phospholipid content in the tissue1 leading to superior valve longevity. Crown PRT's durability, along with its ease of use during procedures and ability to provide excellent hemodynamic performance, makes it an ideal valve for current and future aortic valve replacements." The PMA approval comes on the heels of FDA's go-ahead of the company's Perceval sutureless aortic valve. Release
@FierceMedDev: ICYMI yesterday: IBM Watson, AHA and Welltok to develop workplace heart health program. Article | Follow @FierceMedDev
@VarunSaxena2: Updated w analyst info: Stryker to buy disposable device maker for $2.8B to reduce hospital-acquired infections. Report | Follow @VarunSaxena2
@EmilyWFierce: Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters. FiercePharma story | Follow @EmilyWFierce
> In 2015, Google parent company Alphabet's ($GOOG) "Other Bets," which include med tech Verily along with all its other "moonshot" businesses, had an operating loss of $3.6 billion and revenues of $448 million. More
> Medtronic ($MDT) has added extra-large vessel stent sizes for its Resolute Onyx DES, a next-gen drug-eluting stent. More
> Genetic tests could help motivate workers to put their wearables to good use and make good on employer wellness programs, argues Bloomberg. Story
Biotech News
@FierceBiotech: Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund. Report | Follow @FierceBiotech
@JohnCFierce: Trending: Will Zika frenzy fuel an overnight vaccine R&D miracle? Don't bet on it. More | Follow @JohnCFierce
@DamianFierce: the only thing I miss about working at a newspaper is election night pizza. | Follow @DamianFierce
> GlaxoSmithKline up-sizes its bet on Adaptimmune, racing forward with a cancer immunotherapy. Story
> Sanofi chops into R&D operations in France in latest retrenchment. Article
> Glaxo, Atlas syndicate bankrolls Spero's drive into the clinic with $30M round. Report
Pharma News
@FiercePharma: Roche expects April price cut for Avastin in Japan where Tamiflu sales also hit. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says. Article | Follow @CarlyHFierce
> Pfizer Q4 beats on Prevnar surge, but 2016 guidance disappoints. Story
> Looking to save $1.6B, Sanofi starts with 500-plus job cuts in France. Article
Pharma Manufacturing News
> Troubled Sun Pharma manages U.S. launch of copy of blockbuster Gleevec. Report
> Teva U.K. plant cuts 80 jobs as drugmaker looks for higher skilled workers. News
> CDMO Vetter finishes IT upgrade at German facility. Story
> FDA hands Wockhardt and Ipca more disappointing news. Article
> Allergan CEO suggests expanded Texas plant may be in store for more jobs. More
Drug Delivery News
> Mercator launches microinfusion catheter trial for below-the-knee ischemia. More
> New CRISPR/Cas9 delivery method could offer a clinical pathway. Report
> FDA approves the first extended-release orally disintegrating tablet for ADHD. Item
> Dr. Reddy's wins approval for injectable generic to treat migraines. Story
> Aprecia completes $35M financing to support launch of the first 3-D printed medication. Article
Pharma Asia News
> BMS details new Japan hit to hep C sales. Item
> India's Sun Pharmaceutical meets Feb. 1 deadline for U.S. imatinib launch. More
> Management moves to take Nasdaq-listed Sinovac Biotech private in growing trend. Report
> China's Qiming's fifth U.S. dollar venture fund clocks in at $648 million in commitments. Story
> Amgen says it's awaiting reimbursement details after Japan Repatha nod. Article